East of England Ambulance Service NHS Trust
Melbourn, Cambs, SG8 6EN, United Kingdom
NCT Number: NCT04940897
In this KARMA2 feasibility study the investigators are testing whether ambulance staff can reliably and safely identify patients at high risk of diabetic ketoacidosis using blood ketone meters and start fluid (saline) therapy before arriving at hospital. The investigators aim to include 800 patients in this stepped wedge control study and the results will help decide if a larger study is warranted.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Melbourn, Cambs, SG8 6EN, United Kingdom
Diabetic ketoacidosis (DKA) is a potentially life-threatening condition which requires immediate treatment. National Health Service (NHS) hospital guidelines recommend immediate fluid (saline) therapy. Delays in diagnosis and treatment are known to be associated with health complications and death.
There is an opportunity to involve ambulance crews to improve DKA identification and treatment times; however, currently ambulance staff do not have access to ketone testing, and fluids are recommended only when it is thought a patient is critically unwell.
In this KARMA2 feasibility study the investigators are testing whether ambulance staff can reliably and safely identify patients at high risk of DKA using blood ketone meters and start fluid (saline) therapy before arriving at hospital.
During an 8-month period (4-month control followed by 4-month intervention), 120 ambulance clinicians from the East of England Ambulance Service NHS Trust will receive training to consent 400 patients with hyperglycaemia and unwell patients with diabetes to the control group receiving usual care, followed by determining the presence of ketones using capillary blood testing from a further 400 consenting patients with hyperglycaemia and unwell patients with diabetes. Subsequent patient care will depend on the ketone value obtained: high-risk DKA patients will receive fluid therapy.
Twenty ambulance and hospital clinicians will be invited to an online interview to share views of DKA care and the impact of ambulance blood ketone meters. The results will help the investigators decide if a larger study would be a good idea.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of CareSens ketone meter to identify blood ketone levels and delivery of fluid therapy to those patients at high risk of DKA
Time frame: 18 months
Frequency count of capillary blood glucose level greater than 11mmol/L
Time frame: 18 months
Frequency count of capillary blood ketone level equal to or greater than 3mmol/L
Time frame: 18 months
Progression criteria requires full record completion for a minimum of 70 percent of participants
Time frame: Maximum 18 months
Progression criteria requires adverse event rate to be less than 1 percent of participants
East of England Ambulance Service NHS Trust
Other Gov
Use of Capillary Blood Ketone Meters to Improve Ambulance Service Care of Hyperglycaemic Patients: a Feasibility Study
Acronym: KARMA2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03717896
Acid-Base Imbalance, Acidosis
Boston, Massachusetts, United States
View Trial DetailsNCT07467616
Acid-Base Imbalance, Acidosis
Erbil, Kurdistan Region, Iraq
View Trial DetailsNCT07423559
Acid-Base Imbalance, Acidosis
Tanta, Egypt
View Trial DetailsNCT05402579
Acid-Base Imbalance, Acidosis
Toronto, Ontario, Canada
View Trial Details